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Abstract
Background: Radiation therapy is routinely prescribed for high-grade malignant gliomas. However, the efficacy of
this therapeutic modality is often limited by the occurrence of radioresistance, reflected as a diminished
susceptibility of the irradiated cells to undergo cell death. Thus, cells have evolved an elegant system in response
to ionizing radiation induced DNA damage, where p53, Hsp70 and/or EGFr may play an important role in the
process. In the present study, we investigated whether the content of p53, Hsp70 and EGFr are associated to
glioblastoma (GBM) cell radioresistance.
Methods: Spheroids from U-87MG and MO59J cell lines as well as spheroids derived from primary culture of
tumor tissue of one GBM patient (UGBM1) were irradiated (5, 10 and 20 Gy), their relative radioresistance were
established and the p53, Hsp70 and EGFr contents were immunohistochemically determined. Moreover, we
investigated whether EGFr-phospho-Akt and EGFr-MEK-ERK pathways can induce GBM radioresistance using
inhibitors of activation of ERK (PD098059) and Akt (wortmannin).
Results: At 5 Gy irradiation UGBM1 and U-87MG spheroids showed growth inhibition whereas the MO59J spheroid
was relatively radioresistant. Overall, no significant changes in p53 and Hsp70 expression were found following 5
Gy irradiation treatment in all spheroids studied. The only difference observed in Hsp70 content was the periphery
distribution in MO59J spheroids. However, 5 Gy treatment induced a significant increase on the EGFr levels in
MO59J spheroids. Furthermore, treatment with inhibitors of activation of ERK (PD098059) and Akt (wortmannin)
leads to radiosensitization of MO59J spheroids.
Conclusions: These results indicate that the PI3K-Akt and MEK-ERK pathways triggered by EGFr confer GBM
radioresistance.
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Background
Glioblastoma multiforme (GBM) is among the most
radioresistant tumors [1]. The standard therapy for
GBMs consists of surgery, fractionated radiotherapy with
concomitant temozolamide (TMZ) followed by adjuvant
TMZ. Although this approach showed a significant
increase in median overall survival from 12.1 months for
patients treated with radiotherapy alone to 14.6 months
after the combination of radiotherapy and TMZ [2,3].
The modest increase in survival time after radiotherapy
treatment has been ascribed to the high intrinsic resis-
tance of the GBMs to ionizing radiation [1,4].
Several different culture models have been used to
determine the intrinsic radiosensitivity of gliomas. These
include monolayer cultures of glioma lines, both early and
late passage after initial isolation and spheroids derived
from these cell lines [5,6]. It is assumed that spheroid cul-
tures can better predict the in vivo response compared to
monolayer cultures, since cell-cell contact, variation in cell
cycle, altered metabolism, and diffusion of nutrients and
oxygen or drugs may influence the outcome [7,8].
When irradiated, many cancer cells undergo cell death
by multiple mechanisms of cell death. The main form of
cell death is mitotic catastrophe, which subsequent leads
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Cells might survive the treatment, but lose their clono-
genic capacity, leading to a reduction in clonogenic cell
survival. The actual manifestation of cell death can occur
as necrosis, apoptosis or authophagy [9]. Thus, cells have
evolved an elegant system in response to ionizing radia-
tion induced DNA damage, where p53 has been shown
to play an important role in the process. However, the
p53 gene is the most commonly mutated tumor suppres-
sor gene in malignant gliomas [10], pointing towards p53
status against radiotherapy re s p o n s e[ 1 1 ] .A l s o ,t h eh i g h
expression of members of the Hsp70 family (heat shock
protein of 70 KDa) in high grade gliomas indicates a pos-
sible role of these proteins in resistance to cancer therapy
[12]. The identification of EGFr amplification and muta-
tion in GBM has led to important advances in demon-
strating that the EGFr (in combination with other genetic
alterations) is likely to play an important role in the
pathogenesis of this disease and some studies have corre-
lated their overexpression with radioresistance [13].
Indeed resistance to apoptosis results from changes at
the genomic, transcriptional and post-transcriptional
levels of proteins, protein kinases and their transcrip-
tional factor effectors. The PI3K/Akt and the Ras/Raf/
MEK/ERK signaling cascades play critical roles in the
regulation of gene expression and prevention of apopto-
sis. Components of these pathways are mutated or aber-
rantly expressed in human cancer, notably GBMs [14,15].
Therefore, in the present study the effect of ionizing
irradiation on the expression of p53, Hsp70 and EGFr
was evaluated in GBM spheroids. To this end, spheroids
from U-87MG and MO59J cell lines as well as spheroids
derived from primary culture of tumor tissue of one
GBM patient (UGBM1) were irradiated, their relative
radioresistance established and the p53, Hsp70 and
EGFr contents were immunohistochemically determined.
Moreover, we investigated whether EGFr-phospho-Akt




The U-87MG and MO59J human GBM cell lines were
obtained from the American Type Culture Collection
(Rockville, MD, USA). The primary GBM cells, named
GBM1 was obtained from a 49-years-old white man that
suffers surgery and did not receive chemotherapy or radio-
therapy prior to the surgery procedure. A tumor specimen
was excised and used for tumor processing. The pathologi-
cal diagnosis was GBM based on the histologic features of
vascular proliferation, hypercellularity, mitotic figures,
gemistocytic nuclei, and necrosis. The establishment of
the primary cell culture was performed accordingly to
Farr-Jones [16]. Briefly, after biopsy at least 3 mm of the
pathological fragment was sent to the laboratory to be
processed. Samples were then mechanical dissociate, drop-
ping of the visible stroma and veins. The cells were sus-
pend in trypsin-EDTA for 20 min, centrifuged for 1,400
rpm for 10 min and resuspended in 25 cm
2 flasks with
DMEM/F12 supplemented with 20% fetal calf serum
(FCS) and 4 times the prescribed concentration of non
essential amino acids. During the primary culture we pro-
gressively reduced the FCS concentration to 10%, thus
cells were maintained in complete medium consisting of
DMEM containing 2% (w/v) L-glutamine and 10% (v/v)
FCS, at a temperature of 37
oC, a minimum relative
humidity of 95%, and an atmosphere of 5% CO2 in air. For
experiments, exponentially growing cells between passages
10 to 15 were detached from the culture flasks either
using trypsin-EDTA, or by scraping with a rubber police-
man. Cell viability greater than 95% was confirmed by try-
pan blue exclusion.
Spheroid formation
Once the monolayer cultures became confluent the cells
were trypsinized and spheroids were performed using the
liquid overlay technique of Carlsson and Yuhas [17]. In
brief, exponentially growing monolayer cells were trypsi-
nized and 2x10
6 cells were seeded in Petri dishes pre-
coated with 2% agarose solution mixed in 1:3 ratio with
DMEM supplemented with 10% FCS. After 2 days round
spheroids were formed and those with 200 μmd i a m e t e r
were collected, transferred and culture individually in
agarose-coated wells of 24-well plates (agar 1.5%) with
complete culture medium.
Spheroid treatments and volume determination
The spheroids were irradiated with single doses (5, 10
and 20 Gy) (dose rate 1.14 Gy per minute) using a Tele-
cobalt Theretron Phoenix SR 7510 linear accelerator
(Philips, Eindhoven, The Netherlands), at a source-to-tar-
get distance of 70 cm. Irradiation was applied just after
the harvesting and isolation of spheroids in 24-well
plates. After treatment, the dishes were incubated at 37°
C. For some experiments the 5 Gy radiotherapy was con-
comitant and followed by 48 hours treatment with gefiti-
nib (50 μM) (Astra Zeneca, Macclesfield, Cheshire, UK),
wortmannin (5 μM) (Calbiochem, San Diego, USA) or
PD098059 (50 μM) (Calbiochem, San Diego, USA). The
diameters of at least 12 spheroids were measured with an
inverted microscope each day during 15 days and the
spheroid volume was calculated in accordance to the for-
mula V = 4/3 πr
3,w h e r er=½√ d1.d2 and d = diameter
[18].
Immunohistochemical
Spheroids with 200 μm or more were removed from
culture plates, fixed and embedded in paraffin. For
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sections were mounted on organosilane-coated slides
and dried overnight at 37°C. Sections were deparaffi-
nized in xylene, rehydrated in graded alcohol, and
washed with distillated water. Then the sections were
treated for antigen retrieval using citrate (10 mM, pH
6.0) for 20 min at boiling temperature, followed by 20-
min cool-down in citrate buffer at room temperature.
For monolayer immunohistochemistry, confluent cell
culture slides were fixed on cold acetone for 10 min and
dried at room temperature.
Immunohistochemical procedure was carried on
accordingly to manufactures instructions (Vectastain
ABC System; Dako, Vector, CA, USA). Briefly, endogen-
ous peroxidase activity was quenched by incubation in
3% hydrogen peroxide-methanol solution. Thereafter,
slides were incubated for 20 min in protein block
serum-free (Dako, Carpinteria, CA, USA). The respec-
tive primary antibodies p53, Hsp70, EGFr and phospho-
A k t( D a k o ,C a r p i n t e r i a ,C A ,U S A )w e r ea p p l i e d ,a n d
the slides incubated for 30 min at 37°C and overnight at
4°C in a humidity chamber. Subsequently, slides were
incubated with biotinylated secondary antibody (Vector,
CA, USA) for 30 min. After incubation with VECTAS-
TAIN
® ABC Reagent for 30 min, peroxidase activity
was developed with DAB Substrate-Chromogen System
(Merck, WS, NJ, USA) identifying bound antibody. After
a final wash in distilled water, the slides were lightly
counterstained with hematoxylin, dehydrated in graded
alcohol, cleared with xylene, and mounted with xylene-
based permanent mounting medium.
For all specimens, control slides were processed identi-
cally and at the same time, except that primary antibody
was not applied. Therefore, all differences between the
experimental tissue and the control tissue are ultimately
due to DAB identification of the relevant protein.
Immunohistochemistry analysis
Images from three fields were captured from each section
at × 400 magnification through a microscope-mounted
digital camera (Sony Corp, Tokyo, Japan) built on a Leica/
CME microscopic (Leica, Wetzlar, Germany). The images
were saved TIFF format and transferred onto an image
analysis computer workstation for further analysis.
The immunohistochemistry analyses were realized by
direct visualization and the arbitrary scoring system was
carried on accordingly to Schmidt et al. [19]. The score was
made for both extent (percentage of positive tumor cells:
0%, score = 0; < 5%, score = 1; 5-20%, score = 2; 21-50%,
score = 3; 51-75%, score = 4, > 75%, score 5) and intensity
(absent, score = 0; weak, score = 1; moderate, score = 2;
strong, score = 3). Both scores were multiplied to give a
composite score (0-15) for each tumor cell culture.
ERK phosphorylation assay
Phosphorylation of ERKs 1 and 2 were determined by
probing immunoblots with an anti-phospho-ERK1/2
antibody [20,21]. These determinations provide informa-
tion on the extent of phosphorylation and thus activation
of total ERK by MEK. Thus, spheroids treated with
rhEGF (25 ng/mL) (Gibco BRL-Life Technologies, Long
Island, NY, USA), 5 Gy irradiation, gefitinib (50 μM) or
irradiation plus gefitinib (50 μM) were lysed and centri-
fuged, and aliquots of the supernatants with equal pro-
tein contents were subjected to SDS-PAGE. Separated
proteins were transferred to nitrocellulose filters, which
were blocked overnight at 4°C with 20 mM Tris pH 7.7,
137 mM NaCl, and 0.05% (v/v) Tween 20 (TTBS) con-
taining 5% (v/v) non-fat dry milk (MTTBS). The filters
were rinsed with TTBS, and incubated for 4 h at room
temperature with anti-phospho-ERK1/2 antibodies (New
England Biolabs Inc, Beverly, MA, USA) diluted 1:2,000
in MTTBS. Following three rinses in TTBS, filters were
incubated for 2 h at room temperature with peroxidase-
conjugated anti-mouse IgG diluted 1:500 in MTTBS.
Proteins were detected by enhanced chemiluminescence
(using a horseradish peroxidase-catalyzed and luminol-
based reaction). The blots were stripped for 5 min with 1
mM NaOH, thoroughly washed, blocked, and reprobed
with 1:20,000 diluted anti-ERK1/2 antibodies (Sigma
Chemical Company, St. Louis, MO, USA) that recognize
total ERK1/2.
Statistical Analyses
For the statistical analysis of spheroids, paired t-Student
test was used. All experiments were carried out at least
three times in triplicate. All analysis were performed
with GraphPad Instat (version 3.05; GraphPad Software
Inc.; San Diego, CA, USA).
Results
Effect of ionizing radiation on human GBM spheroids
growth
The volume growth of GBM spheroids after treatment
with ionizing irradiation was determined. Escalating sin-
gle doses of ionizing radiation (5, 10 and 20 Gy) pro-
moted a dose-dependent decrease in growth for all three
human GBM spheroids: UGBM1, U-87MG and M059J
(Figure 1). The assays revealed a significant (p < 0.05)
inhibition, within 72 h of 20 Gy irradiation of spheroid
volume for all cell cultures. At lower doses irradiation (5
and 10 Gy) the UGBM1, U-87MG and M059J spheroids
demonstrated different relative sensitivities. The spher-
oids that were relatively radiosensitive at these doses
were U-87MG and UGBM1. These spheroids demon-
strated a significant suppression of growth within 3 days
of 5 Gy irradiation for U-87MG spheroids and within 9
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the dose of 5 Gy irradiation reached 66% of reduction in
U-87MG spheroid growth and 40% for UGBM1. Further-
more, 10 Gy irradiation significantly (p < 0.05) decreased
the growth of U-87MG (within 24 h after irradiation,
data not shown) and UGBM1 (within 6 days after irradia-
tion) (Figure 1), inducing 82% of inhibition capacity in U-
87MG and 71% in UGBM1 spheroids. While in MO59J
spheroids the inhibition capacity (56%) was observed
only at day 15. Thus, U-87MG spheroids were the most
radiosensitive, while UGBM1 spheroids showed inter-
mediate radiosensitivity. Conversely, MO59J spheroids
presented relative radioresistance, when compared to U-
87MG and UGBM1 spheroids. Inhibition of cell prolif-
eration was observed only when MO59J spheroids were
subjected to the higher irradiation doses (10 and 20 Gy)
and after longer postradiation intervals (Figure 1).
Effect of ionizing radiation on the p53 and Hsp70
contents on human GBM spheroids
Since the distinct sensitivity of the GBM spheroids studied
to radiation-mediated toxicity might reflect differences in
their susceptibility to undergo cell death, the effect of 5 Gy
on p53 and the cytoprotective Hsp70 contents was first
investigated.
In the spheroids established from UGBM1, U-87MG
and MO59J cell cultures, the p53 expression was higher
than 75% and the immunopositivity was found on the
cytoplasm and nucleus. Also, p53 was uniformly distribu-
ted on all spheroids zone. No wide variety in the percen-
tage of p53 immunoreactive tumor cells was documented
between all three tumor cell spheroids. Overall, no signifi-
cant changes in p53 expression were found following 5 Gy
irradiation treatment in all spheroids studied (Figures 2
and 3).
At cellular level, immunohistochemistry assays reveal
high accumulation of Hsp70 protein in all three GBM
spheroids studied. Nevertheless, the location of the label
varied with 5 Gy irradiation treatment, especially in
MO59J spheroids. All control spheroids presented Hsp70
widely distributed on the spheroids. The irradiation did
not induce significant alterations on the total Hsp70 con-
tents on the GBM spheroids, but with 5 Gy treatment,
MO59J spheroids showed a periphery distribution of the
label on 6 days after irradiation (Figures 2 and 3). Taking
into account that the high expression of Hsp70 on GBMs
may induce resistance to cancer therapy [12,22] and that
the ionizing radiation acts mainly in proliferating cells,
which are mostly in the periphery of the tumor, it is pos-
sibly to suggest that Hsp70 can be involved on the
MO59J GBM radioresistance.
Effect of ionizing radiation on the EGFr signaling on
human GBM spheroids
It is well known that the amplification of EGFr in GBM is
related to the high cellular growth response. For this rea-
son, we also investigated if the EGFr contents can be asso-
ciated to the effect of 5 Gy irradiation on the spheroids.
Then, immunohistochemistry analysis revealed high inci-
dence of EGFr in all three GBM spheroids with more than
75% of incidence in the cytoplasm of the cells through all
spheroid regions. Moreover, at 5 Gy irradiation treatment
it was detected a significant increase on the EGFr levels in
MO59J spheroids (p < 0.05) (Figures 2 and 3). This data
suggest that EGFr is associated to GBM cellular response
to radiotherapy, possibly protecting radioresistant cells
against death.
Radiation therapy may enhance the EGFr intracellular
activation pathways, which in turn may induce prolifera-
tion, blockage of apoptosis and contribute to promote
the tumor growth. Thus, we further examined whether
the MEK-ERK cascade was involved in the transduction
of the signals generated by EGFr in response to irradia-
tion. To this end, ERK activation was assessed. In fact, 5
Gy irradiation promoted high phosphorylation on ERK1/
2 in the same way as treatment with EGF in MO59J
Figure 1 Effects of irradiation on UGBM1 (a), U-87MG (b) and MO59J (c) human GBM spheroids proliferation. Volume of non-irradiated
or irradiated (5, 10 or 20 Gy) spheroids were determined every 3 days during a period of 15 days by measuring the spheroids diameter. Data
was plotted as the mean ± SD of 24 GBM spheroids of three different experiments.
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ished the phosphorylation of the ERK1/2 (Figure 4), sug-
gesting that EGFr-MEK-ERK signaling is involved on the
GBM radiation response.
Given that PI3K/Akt is another very important intra-
cellular pathway involved in EGFr activation [23], Akt
functions could trigger growth and antiapototic survival
of GBM cells after irradiation. To test this hypothesis,
we next examined whether phospho-Akt contents can
be affected by ionizing radiation. A positive phospho-
Akt immunostaining was detected in all spheroids sam-
ples. At 5 Gy irradiation the phospho-Akt content on
MO59J spheroids presented an increase about 2 times
(p < 0.05) (Figure 5). These data indicate that PI3K/Akt
Figure 2 p53, Hsp70 and EGFr immunohistochemical expression in UGBM1, U-87MG and MO59J spheroids following irradiation.
Immunostaining score was calculated for non-treated (control) or irradiated (5 Gy) as determined 24 h (left column) and 6 days (right column)
after treatment. Arbitrary scoring system was calculated as described in Methods section. Data was plotted as the mean ± SD of three different
experiments. *Significantly different from control (p < 0.05).
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relative radioresistant MO59J spheroids.
To evaluate mechanisms underlying the cellular
response to ionizing radiation described above, we next
examined the effect of the inhibition of the two main path-
ways of EGFr signaling, using a PI3K inhibitor -
wortmannin and a MEK inhibitor- PD098059 on the
MO59J spheroids growth after irradiation. Thus, 5 Gy irra-
diation treatment was concomitant and followed by 48
hours treatment with gefitinib (50 μM), wortmannin (5
μM) or PD098059 (50 μM). When PD098059 (50 μM) was
added, the spheroids presented a significant decrease on
their growth when compared to control. Combined radia-
tion treatment showed significantly growth reduction of
40% (p < 0.05). Besides, the addition of the PI3K inhibitor
- wortmannin (5 μM), which suppress the phosphorylation
of Akt [24], significantly reduced the MO59J spheroids
proliferation and a significant reduction of 68% the spher-
oid volume was observed in addition to 5 Gy irradiation (p
< 0.05) (Figure 6). Together, these results suggest that the
PI3K-Akt and MEK-ERK signaling are both triggering
EGFr signaling against GBM radiotherapy effects.
Discussion
It is widely accepted that the inherent radioresistance of
some tumors is an important factor limiting for their
Figure 3 Representative photomicrographs of the p53 content evaluated by immunohistochemistry in UGBM1 human GBM spheroids
(A); Hsp 70 content following 5 Gy irradiation in MO59J spheroids (B); EGFr contents in no-irradiated (control) (C) and 5 Gy irradiated
MO59J spheroids (D). EGFr antibody clone H11, recognizes wild-type EGFr and the deleted mutant form (EGFrvIII). Original magnification × 400.
Figure 4 Phosphorylation of ERK1/2 in MO59J spheroids after
treatment with 5 Gy irradiation or gefitinib, alone or in
combination. ERK1/2 phosphorylation was determined by
phospho-ERK immunoblotting using anti-phospho ERK1/2 antibody,
and anti-ERK1/2 antibodies against total ERK1/2. Lane 1 - control;
lane 2- rhEGF (25 ng/mL); lane 3 - 5 Gy irradiation, lane 4 - gefitinib
(50 μM) and lane 5 - 5 Gy irradiation plus gefitinib (50 μM).
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demonstrated by local recurrence of the irradiated volume
[25]. Then, an understanding of the molecular responses
of GBM cells following irradiation may offer potential new
targets for future therapy. In this study we have assessed
the relative radiosensitivities of three types of GBM spher-
oids. We found that in response to radiation treatment, all
cultures demonstrated a dose-dependent inhibition on cell
proliferation. However, we could observe a clear difference
in their radiosensitivity, which are in accordance with the
clinical heterogeneity in GBM radiosensitivity.
It is assumed that spheroid cultures of glioma cell lines
can better predict the in vivo response than monolayer
cultures, since cell-cell contact, variation in cell cycle,
altered metabolism, and diffusion of nutrients, oxygen or
drugs may influence the outcome. The advantage of cell
line spheroids is that they are relatively easy to obtain
and to maintain in culture. Treatment-related changes of
the growth kinetic of spheroids and the outgrowth of
tumor cells present established and reproducible end-
points [26]. Using spheroids from biologically different
human GBM cell lines and one from primary GBM cul-
t u r e ,w eh a v es h o w n ,a sr e p o r t e dp r e v i o u s l y[ 2 7 ] ,t h a t
radiation consistently reduces the growth potential of all
the GBM spheroids investigated. Another study exam-
ined whether, growth conditions also affect tumor cell
radioresistance and radiation-induced DNA double
strand breaks in a chromatin-dependent manner [28].
Essentially, that study showed that a 3D microenviron-
ment results in increased tumor cell radioresistance
mediated by less DNA double strand breaks and chromo-
somal aberrations since 3D culture conditions leads to
increased amount of heterochromatin. In line with these
findings, our data reveal that growth conditions contri-
bute to the regulation of GBM cell fate and responsive-
ness to external stimuli since the U-87MG cell line was
mentioned as a radioresistant in monolayer culture in a
previous study from our lab and others [22]. While, the
U-87MG spheroid model was more sensitive to ionizing
radiation than MO59J spheroids. For instance, in MO59J
spheroids, in which low radiation doses (5 and 10 Gy) are
not significantly affecting cell proliferation, a permanent
cell cycle or anti cell death mechanisms ensue.
GBM are generally lethal within 2 years of diagnosis due
in part to the intense cell death resistance of its cancer
cells, hence poor therapeutic response to radiotherapy.
Figure 5 Phospho-Akt immunohistochemical expression in
UGBM1, U-87MG, and MO59J spheroids following irradiation.
Immunostaining score was calculated for non-treated control (■)o r
5 Gy irradiated (□) as determined 24 h after treatment. Arbitrary
scoring system was calculated as described in Methods section.
Data was plotted as the mean ± SD of three different experiments.
*Significantly different from control (p < 0.05).
Figure 6 MO59J human GBM spheroids proliferation after treatment with 5Gy irradiation, (a) PD098059 (50 μM), (b) wortmannin (5
μM), alone or in combination. Volume of spheroids was determined every 3 days during a period of 15 days by measuring the spheroids
diameter. Data was plotted as the mean ± SD of 24 GBM spheroids of three different experiments.
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believed to be at the basis of the resistance to ionizing
radiation seen in many GBM patients [1]. The p53 tumor
suppressor gene is frequently mutated in human malig-
nances, including gliomas. In fact, the alterations of p53
gene play a significant role in the initiation and progres-
sion of astrocytomas [29-31]. Therefore, therapies aimed
at restoring wild-type function or specifically targeting
cells harbouring mutant p53 have been explored in precli-
nical models of gliomas [32-35], leading to clinical trial
using adenovirus as gene delivery vector [36]. However,
these strategies are controversial since some investigators
have found that apoptosis can occur through alternative
signaling pathways independent of p53 status [37-39]. In
agreement, in our study, the irradiation treatment did not
promote changes on p53 contents in all three GBM spher-
oids studied, which is also in accordance to most investi-
gations that have found that p53 mutation or
overexpression is not a significant prognostic factor for
survival in GBM [40]. This may reflect the existence of
other molecular alterations that abrogate p53 function,
such as mdm-2 amplification or p14
ARF and BCL2-like-12
alterations [38,39,41]. Hence, it has been proposed that
several events can be induced or suppressed to bring
about cell death.
Solid tumors are generally stressed tissues, frequently
expressing high levels of numerous proteins, especially
members of the chaperone and heat shock protein (HSP)
family. The most stress-inducible Hsp, Hsp70 (also known
as Hsp72), is an antiapoptotic chaperone expressed abun-
dantly in human tumors [42]. The tumorigenic potential
of Hsp70 has been suggested to depend on its ability to
transform cells and/or on its antiapoptotic properties [12].
I nf a c t ,i nap r e v i o u ss t u d yw eh a v ed e m o n s t r a t e dt h a t
irradiation promotes increase of Hsp70 in radioresistant
GBM cell line [22]. In the present study, the particularly
high concentrations of Hsp70 on the periphery region of
the spheroids following irradiation on the radioresistant
MO59J spheroids could, at least in part, reflect a tolerance
of the proliferating cells to survive despite of the stress
conditions through activation of antiapoptotic pathways.
In agreement to our data, it has been demonstrated that
gene silencing by specific shRNA targeted against HSP70
resulted in significant inhibition of cell growth, G0/G1
arrest and increased apoptosis in the human colon cancer
cell line HT29 [43].
Our findings suggest that EGFr may contribute to the
radioresistance in GBMs. Several lines of evidence indicate
that the EGFr signaling pathway may be an important fac-
tor in determining tumor cell response to ionizing radia-
tion. EGFr blockage using a specific monoclonal antibody
- C225, enhances radiosensitivity of U-87MG GBM cells
[44]. Furthermore, the antitumor effect of anti-EGFr
monoclonal antibody in combination with radiotherapy
has been thought to result from the enhancement of the
inhibition of EGFr signaling, increasing the cytotoxic effect
of the radiation [13,45]. Consistent with these results we
found that treatment with Gefitinib and irradiation dimin-
ished the ERK activation triggered by EGFr, supporting a
notion that the EGFr signaling can be related to GBM
radiation response [13].
The radiation therapy may enhance the EGFr intracellu-
lar activation pathways after treatment, which in turn may
contribute against irradiation induced cell death. EGFr sti-
mulation by the growth factor can lead to activation of
phosphatidylinositol 3-kinase (PI3K), which catalyzes the
conversion of phosphatidylinositol 4,5-biphosphate (PIP2)
into phosphatidylinositol 3,4,5-triphosphate (PIP3). Finally,
membrane-associated PIP3 attracts and activates the pro-
tein serine-threonine kinase Akt [46]. In fact, our results
have shown an increase on the phospho Akt contents in
the radioresistant MO59J spheroids. In addition, we found
that the PI3K inhibitor - wortmannin leads to radiosensiti-
zation of these spheroids with a greater effect than the
MEK inhibitor - PD098059. Thus, together, our data sug-
gest that EGFr signaling induced by radiation is mediated
by MEK-ERK pathway, but is mainly determined by PI3K-
Akt signaling in the radioresistant GBM.
The identification of Akt as a key regulator of cellular
survival has significant implications for current glioma
biology [46]. Combined activation of Ras and Akt in
neural progenitors induced GBM formation in mouse
[47]. Elevated Ras activity and the phosphorylated Akt, as
well as the deletion of PTEN, which downregulate Akt
signaling, has been demonstrated in surgical specimens
derived from human gliomas [48]. Therefore, deletion of
active PTEN and overexpression of active Ras, combined
with the overexpression of active PI3K, can renders can-
cer cells resistant to apoptosis by blocking adaptive cellu-
lar apoptosis through the hyperactivation of Akt [24].
In summary, the results of the current study demon-
strate that EGFr signaling mediated by MEK-ERK and
PI3K-Akt is involved in the response of GBM spheroids
to radiation. Thus, we can propose that MEK-ERK and
PI3K-Akt signaling are associated to protective effects
against radiation induced cell death in radioresistant
GBMs. Although the findings of this study cannot pro-
vide a mechanistic explanation to correlate these phe-
nomena, we suggest that the protective role of EGFr
signaling should be further investigated as a potential
novel target to increase the sensitivity of human GBM
to radiation.
Conclusion
In conclusion, our findings indicate that the PI3K-Akt
and MEK-ERK pathways may have a critical role in
radiosensitivity of GBM cells. Therefore, selective inhibi-
tors that specifically target PI3K-Akt and MEK-ERK
Fedrigo et al. Radiation Oncology 2011, 6:156
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Page 8 of 10signaling may have important therapeutic implications
when used in combination with radiation in the treat-
ment of GBM patients.
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